Ovarian cancer is cancer that starts in the ovaries. The ovaries are the female reproductive organs that produce eggs.
VACCINE CVAC TO TREAT OVARIAN CANCER There is a quiet bit of research into developing a vaccine, not to prevent, but to treat ovarian cancer. The idea behind these vaccines is to stimulate the body's own immune system to target and destroy tumor cells. An Australian company, Prima Biomed, has performed a number of clinical trials with its vaccine CVac. Using a novel technology, CVac's immunotherapy works by teaching the immune system to recognise the tumor cells as foreign. Dendritic cells are removed from the patient and stimulated with mannan fusion protein (MFP), consisting of the antigenic portion of the tumor antigen mucin-1 (MUC-1) fused to the immune-enhancing sugar mannan. The cells are then reinfused back into the patient to generate primarily a T-cell-based immune response against the MUC-1-expressing tumor.
VACCINE NY-ESO-1 TESTED FOR OVARIAN CANCER Cornell University's vaccine for ovarian cancer and melanoma in clinical trials. The Bioproduction Facility at Cornell has produced a batch of the cancer vaccine. The melanoma trial is being conducted at New York University Medical Center, while the ovarian cancer vaccine trial is at the Roswell Park Cancer Institute in Buffalo, N.Y. The trials are assessing the safety and the anti-tumor immune response of the so-called NY-ESO-1 recombinant protein cancer vaccine alone and in combination with other agents. The goal of these trials is to maximize the body's immune response to the NY-ESO-1 protein. This vaccine is not intended to prevent cancer, but one that will stimulate the body to fight an existing tumor. The challenge is that the vaccine is made from molecules -- proteins -- that are found in our own bodies and do not normally induce strong immune responses.